ARMATA PHARMACEUTICALS, INC. Financing Cash Flow
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Financing Cash Flow of $28.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $27.88M.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $641.00K, a 93.58% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $658.00K.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $14.97M.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $25.61M, a 26.73% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $34.96M, a 35.25% decline from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $53.99M, a 22.66% increase from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $44.02M, a 72.49% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $27.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $28.52M 10-Q · filed 2026-08-12 | $29.18M derived: sum of 3 quarters · filed 2026-08-12 | $44.15M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $641.00K 10-Q · filed 2026-05-13 | $1.30M derived: sum of 2 quarters · filed 2026-05-13 | $16.27M derived: sum of 3 quarters · filed 2026-05-13 | $16.27M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $15.63M derived: sum of 2 quarters · filed 2026-03-25 | $15.63M derived: sum of 3 quarters · filed 2026-08-12 | $25.61M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $14.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.97M derived: sum of 2 quarters · filed 2026-08-12 | $24.95M 10-Q · filed 2025-11-12 | $24.95M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.99M 10-Q · filed 2026-08-12 | $9.99M derived: sum of 3 quarters · filed 2026-08-12 | $9.93M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $9.99M 10-Q · filed 2026-05-13 | $9.99M derived: sum of 2 quarters · filed 2026-05-13 | $9.93M derived: sum of 3 quarters · filed 2026-05-13 | $10.01M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$61.00K derived: sum of 2 quarters · filed 2026-03-25 | $27.00K derived: sum of 3 quarters · filed 2026-03-25 | $34.96M 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $27.00K derived: sum of 2 quarters · filed 2025-11-12 | $34.96M 10-Q · filed 2025-11-12 | $34.91M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $35.02M 10-Q · filed 2025-08-12 | $34.98M derived: sum of 3 quarters · filed 2025-08-12 | $59.78M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $34.93M 10-Q · filed 2025-05-14 | $34.89M derived: sum of 2 quarters · filed 2025-05-14 | $59.69M derived: sum of 3 quarters · filed 2025-05-14 | $59.33M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $24.76M derived: sum of 2 quarters · filed 2025-03-21 | $24.39M derived: sum of 3 quarters · filed 2025-03-21 | $53.99M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $24.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $24.44M derived: sum of 2 quarters · filed 2024-11-13 | $54.03M 10-Q · filed 2024-11-13 | $53.53M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $29.23M 10-Q · filed 2024-08-13 | $28.73M derived: sum of 3 quarters · filed 2024-08-13 | $28.76M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $29.59M 10-Q · filed 2024-05-07 | $29.09M derived: sum of 2 quarters · filed 2024-05-07 | $29.13M derived: sum of 3 quarters · filed 2024-05-07 | $28.98M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$469.00K derived: sum of 2 quarters · filed 2024-03-21 | -$615.00K derived: sum of 3 quarters · filed 2024-03-21 | $44.02M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$115.00K derived: sum of 2 quarters · filed 2023-11-14 | $44.52M 10-Q · filed 2023-11-14 | $51.55M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $44.48M 10-Q · filed 2023-08-14 | $51.52M derived: sum of 3 quarters · filed 2023-08-14 | $51.61M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $44.63M 10-Q · filed 2023-05-11 | $51.67M derived: sum of 2 quarters · filed 2023-05-11 | $51.76M derived: sum of 3 quarters · filed 2023-05-11 | $51.57M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $7.12M derived: sum of 2 quarters · filed 2023-03-16 | $6.94M derived: sum of 3 quarters · filed 2023-03-16 | $25.52M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$99.00K derived: sum of 2 quarters · filed 2022-11-09 | $18.48M 10-Q · filed 2022-11-09 | $18.91M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $18.39M 10-Q · filed 2022-08-11 | $18.83M derived: sum of 3 quarters · filed 2022-08-11 | $18.89M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $18.58M 10-Q · filed 2022-05-12 | $19.01M derived: sum of 2 quarters · filed 2022-05-12 | $19.07M derived: sum of 3 quarters · filed 2022-05-12 | $19.38M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $492.00K derived: sum of 2 quarters · filed 2022-03-17 | $798.00K derived: sum of 3 quarters · filed 2022-03-17 | $23.21M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $366.00K derived: sum of 2 quarters · filed 2021-11-10 | $22.78M 10-Q · filed 2021-11-10 | $22.78M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $22.72M 10-Q · filed 2021-08-12 | $22.72M derived: sum of 3 quarters · filed 2021-08-12 | $22.72M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $22.41M 10-Q · filed 2021-05-13 | $22.41M derived: sum of 2 quarters · filed 2021-05-13 | $22.41M derived: sum of 3 quarters · filed 2021-05-13 | $32.39M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $9.97M derived: sum of 3 quarters · filed 2021-03-18 | $8.97M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $9.97M derived: sum of 2 quarters · filed 2020-11-12 | $8.97M 10-Q · filed 2020-11-12 | $15.06M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $9.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $8.97M 10-Q · filed 2020-08-13 | $15.06M derived: sum of 3 quarters · filed 2020-08-13 | $15.02M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | -$1.00M 10-Q · filed 2020-05-14 | $5.00K 10-Q · filed 2019-05-06 | $5.09M derived: sum of 2 quarters · filed 2020-05-14 | $5.04M derived: sum of 3 quarters · filed 2020-05-14 | $4.84M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | $6.04M derived: sum of 2 quarters · filed 2019-03-25 | $5.84M derived: sum of 3 quarters · filed 2019-03-25 | $12.45M 10-K · filed 2019-03-25 | |
| 2018-09-30 | -$44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$248.00K derived: sum of 2 quarters · filed 2018-11-08 | $6.36M 10-Q · filed 2018-11-08 | $6.16M derived: sum of 4 quarters · filed 2019-05-06 | |
| 2018-06-30 | -$204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $6.41M 10-Q · filed 2018-08-09 | $6.20M derived: sum of 3 quarters · filed 2019-05-06 | $5.59M derived: sum of 4 quarters · filed 2019-05-06 | |
| 2018-03-31 | $6.61M 10-Q · filed 2019-05-06 | $6.40M derived: sum of 2 quarters · filed 2019-05-06 | $5.79M derived: sum of 3 quarters · filed 2019-05-06 | $15.49M derived: sum of 4 quarters · filed 2019-05-06 | |
| 2017-12-31 | -$206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | -$817.00K derived: sum of 2 quarters · filed 2019-03-25 | $8.88M derived: sum of 3 quarters · filed 2019-03-25 | $8.67M 10-K · filed 2019-03-25 | |
| 2017-09-30 | -$611.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $9.08M derived: sum of 2 quarters · filed 2018-11-08 | $8.88M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $9.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $9.49M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$205.00K 10-Q · filed 2018-05-15 | ||||
| 2016-12-31 | $7.23M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |